NYSE:GKOSGlaukos Stock Price, Forecast & News

Glaukos' stock was trading at $38.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GKOS shares have decreased by 3.4% and is now trading at $37.32. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Glaukos.

Glaukos is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Glaukos.

Glaukos Corp (NYSE:GKOS) issued its quarterly earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.09. The medical instruments supplier earned $55.30 million during the quarter, compared to analysts' expectations of $55.05 million. Glaukos had a negative net margin of 15.65% and a negative return on equity of 6.95%. The firm's revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.04) EPS. View Glaukos' earnings history.

Glaukos updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55-55.3 million, compared to the consensus revenue estimate of $60.81 million.

10 brokerages have issued 1 year price objectives for Glaukos' shares. Their forecasts range from $34.00 to $67.00. On average, they expect Glaukos' share price to reach $47.22 in the next year. This suggests a possible upside of 26.5% from the stock's current price. View analysts' price targets for Glaukos.

News articles about GKOS stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Glaukos earned a news impact score of -2.1 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Glaukos.

Some companies that are related to Glaukos include Penumbra (PEN), Novocure (NVCR), Tandem Diabetes Care (TNDM), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), Inari Medical (NARI) and Cantel Medical (CMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include Alibaba Group (BABA), NVIDIA (NVDA), PTC Therapeutics (PTCT), Paypal (PYPL), Marvell Technology Group (MRVL), Boeing (BA), Micron Technology (MU), Shopify (SHOP), Baidu (BIDU) and Caterpillar (CAT).

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by many different institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View institutional ownership trends for Glaukos.

GKOS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and Thomas William Burns. View insider buying and selling activity for Glaukos.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GKOS stock can currently be purchased for approximately $37.32.

Glaukos has a market capitalization of $1.65 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 437 workers across the globe.

The official website for Glaukos is www.glaukos.com.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]